Dupuytren's Contracture Clinical Trial
Official title:
Health-Related Quality of Life in Patients With Dupuytren's Disease: A Prospective Cohort Study.
Verified date | July 2011 |
Source | McMaster University |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Ethics Review Committee |
Study type | Observational |
Main Research Questions:
We want to measure the change in quality of life in Dupuytren's disease patients who do and
do not undergo surgery. Also, we want to test the validity of health related quality of life
measurements in patients with Dupuytren's disease.
Why is this research important? Some patients with Dupuytren's contracture require excision
surgery or palmar fasciectomy. Other patient's with Dupuytren's contracture do not require
surgery; however, these patients may need surgery in the future. No studies have reported
the health-related quality of life of patients with Dupuytren's disease whether related to
surgical intervention or not.
What is being studied? We are studying the difference and change in health-related quality
of life in patients suffering from Dupuytren's disease who require excision surgery and do
not require surgery.
Status | Completed |
Enrollment | 51 |
Est. completion date | July 2011 |
Est. primary completion date | July 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - patients who have the diagnosis of Dupuytren's disease - able to comprehend English to complete the self-reported questionnaires - willing to provide informed consent. Exclusion Criteria: - patients who have had previous Dupuytren's contracture surgery on the same hand - patients who have carpal tunnel syndrome, rheumatoid arthritis, connective tissue disorder, tenosynovitis, or another condition that could affect quality of life - patients who are under the age of 18 years. |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Canada | St. Joseph's Healthcare | Hamilton | Ontario |
Lead Sponsor | Collaborator |
---|---|
Hamilton Health Sciences Corporation | McMaster University |
Canada,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01715467 -
CORRECT: COmmunity RegistRy Study Evaluating Dupuytren's Contracture Treatment
|
N/A | |
Completed |
NCT01674634 -
Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures
|
Phase 3 | |
Completed |
NCT01407068 -
Administration of Two Injections for Multiple Dupuytren's Contractures
|
Phase 3 | |
Completed |
NCT00528931 -
A Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's Contracture
|
Phase 1 | |
Completed |
NCT00565019 -
Effects of Steroid Injection With Percutaneous Needle Aponeurotomy in Dupuytren's Contracture
|
Phase 3 | |
Completed |
NCT01588353 -
Collagenase Option for Reduction of Dupuytren's Contracture in Japan
|
Phase 3 | |
Completed |
NCT01444729 -
Post Approval Commitment Study
|
N/A | |
Terminated |
NCT05877066 -
Real-World Data Study to Understand Participant Treatment Outcomes for Dupuytren's Contracture
|
||
Completed |
NCT01229436 -
Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)
|
Phase 3 | |
Completed |
NCT01265420 -
Efficacy and Safety of Xiaflex Injection for Treatment of Dupuytren's Contracture of the Thumb
|
Phase 4 | |
Completed |
NCT00931567 -
Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound Healing
|
Phase 2/Phase 3 | |
Completed |
NCT00528606 -
AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture
|
Phase 3 | |
Completed |
NCT00004409 -
Phase II Randomized Study of Collagenase in Patients With Residual Type Dupuytren's Disease
|
Phase 2 | |
Completed |
NCT00014742 -
Phase III Randomized Study of Collagenase in Patients With Residual Stage Dupuytren's Disease
|
Phase 3 |